
Lindsay B Kilburn MD
Pediatric Neuro-Oncology
Attending physician in Neuro-Oncology and Director of Experimental Therapeutics for the Brain Tumor Institute at Children's National Hospital and Associate Professor of Pediatrics at the George Washington School of Medicine and Health Sciences
Join to View Full Profile
6701 Fannin StHouston, TX 77030
Phone+1 832-822-4890
Fax+1 713-798-1144
Dr. Kilburn is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- I am board certified in pediatric hematology and oncology as well as clinical pharmacology. I care for children with newly diagnosed and recurrent brain and spinal cord tumors. My research focuses on the development and translation of new therapies for children with brain tumors with a particular focus on novel therapies for glioma and medulloblastoma and combination therapies with focused ultrasound.
Education & Training
- Baylor College of MedicineFellowship, Pediatric Hematology/Oncology, 2004 - 2007
- Old Dominion UniversityResidency, Pediatrics, 2001 - 2004
- Eastern Virginia Medical SchoolClass of 2001
Certifications & Licensure
- DC State Medical License 2010 - 2027
- TX State Medical License 2007 - 2011
- VA State Medical License 2001 - 2004
- American Board of Pediatrics Pediatric Hematology-Oncology
Clinical Trials
- Vorinostat Combined With Isotretinoin and Chemotherapy in Treating Younger Patients With Embryonal Tumors of the Central Nervous System Start of enrollment: 2009 Feb 25
- PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children Start of enrollment: 2012 Dec 13
- Pomalidomide in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors Start of enrollment: 2015 Jul 14
- Join now to see all
Publications & Presentations
PubMed
- A Phase 2 PBTC Study of Selumetinib for Recurrent/Progressive Pediatric Low-Grade Glioma: Strata 2, 5, and 6 with Long-term Outcomes on Strata 1, 3, and 4.Jason Fangusaro, Arzu Onar-Thomas, Tina Young Poussaint, Shelly Lensing, Azra H Ligon
Neuro-Oncology. 2025-04-17 - Author Correction: The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial.Lindsay B Kilburn, Dong-Anh Khuong-Quang, Jordan R Hansford, Daniel Landi, Jasper van der Lugt
Nature Medicine. 2025-04-16 - 1 citationsRetrospective Comparison of Targeted Anticancer Drugs Predicted by the CNS-TAP Tool Versus Those Selected by a Molecularly Driven Tumor Board in Children With DIPG.Holly J Roberts, Karthik Ravi, Bernard L Marini, Allison Schepers, Cassie Kline
Journal of Pediatric Hematology/oncology. 2025-01-01
Journal Articles
- Clinically Relevant and Minimally Invasive Tumor Surveillance of Pediatric Diffuse Midline Gliomas Using Patient-Derived Liquid BiopsyEugene I Hwang, Cassie Kline, Soonmee Cha, Michael Prados, Lindsay B Kilburn, Nalin Gupta, Roger J Packer, Suresh N Magge, Clinical Cancer Research
Press Mentions
- Evolving Treatment Approaches in Pediatric Low-Grade GliomaApril 8th, 2025
- SonALAsense Forges Ahead with First Patient Dosing for Devastating Childhood Brain CancerSeptember 13th, 2022
- “Liquid Biopsies” Could Track Diffuse Midline GliomasAugust 21st, 2019
- Join now to see all
Professional Memberships
- Member
- Society of Neuro-OncologyMember
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: